다우존스 지수

실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Lyell Immunopharma Inc (LYEL)
Lyell Immunopharma Inc (LYEL) 뉴스

LYEL

Lyell Immunopharma (LYEL)

Lyell Immunopharma Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:LYEL

1 2 3 4 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/03/06	06:30	GlobeNewswire Inc.	Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting	NASDAQ:LYEL	Lyell Immunopharma Inc
2024/02/29	06:07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LYEL	Lyell Immunopharma Inc
2024/02/29	06:05	GlobeNewswire Inc.	Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023	NASDAQ:LYEL	Lyell Immunopharma Inc
2024/02/27	06:05	GlobeNewswire Inc.	Lyell Immunopharma Announces Participation in March Investor Conferences	NASDAQ:LYEL	Lyell Immunopharma Inc
2024/02/14	10:24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LYEL	Lyell Immunopharma Inc
2024/02/14	10:22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LYEL	Lyell Immunopharma Inc
2024/02/14	10:19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LYEL	Lyell Immunopharma Inc
2024/01/04	06:05	GlobeNewswire Inc.	Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/11/21	10:55	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/11/21	10:54	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/11/21	10:52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/11/21	06:26	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/11/10	06:05	GlobeNewswire Inc.	Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/11/08	06:14	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/11/08	06:08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/11/08	06:05	GlobeNewswire Inc.	Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/10/31	22:00	GlobeNewswire Inc.	Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/09/27	22:00	GlobeNewswire Inc.	Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/09/11	22:16	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/09/11	21:00	PR Newswire (US)	Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/09/11	21:00	GlobeNewswire Inc.	Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/09/01	05:05	GlobeNewswire Inc.	Lyell Immunopharma to Participate in Upcoming Investor Conferences	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/08/09	05:21	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/08/09	05:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/08/09	05:05	GlobeNewswire Inc.	Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/07/06	05:05	GlobeNewswire Inc.	Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/06/22	05:55	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/06/21	05:52	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/06/21	05:46	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:LYEL	Lyell Immunopharma Inc
2023/06/21	05:44	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:LYEL	Lyell Immunopharma Inc

검색 관련기사 보기:NASDAQ:LYEL

1 2 3 4 다음 >>

Financial Select Sector

BNP Paribas (QX)

US Dollar vs Euro

Bank of America

Energy Select Sector SPDR

Deutsche Telekom (QX)

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관